NEJM: Trastuzumab deruxtecan vs Trastuzumab emtansine in HER2-positive metastatic breast cancer

Breast cancer is the most common and deadly cancer in women worldwide, and approximately 20% of breast cancer patients are HER2-positive
.

Although HER2-targeted therapy has significantly improved disease outcomes, most patients with locally advanced or metastatic disease have disease progression following targeted therapy

Breast cancer researchers reported the efficacy of trastuzumab deruxtecan in patients with breast cancer whose disease had progressed after trastuzumab plus paclitaxel

Progression-free survival after 12 months was 75.
8% in the trastuzumab deruxtecan group and 34.
1% in the trastuzumab emtansine group (0.

Trastuzumab deruxtecan treatment reduces the risk of disease progression in patients

Trastuzumab deruxtecan treatment reduces the risk of disease progression in patients Trastuzumab deruxtecan treatment reduces the risk of disease progression in patients

The study concluded that for patients with HER2-positive metastatic breast cancer who had progressed after receiving trastuzumab plus paclitaxel, trastuzumab deruxtecan was superior to trastuzumab emtansine in reducing the risk of disease progression or death, but trastuzumab deruxtecan treatment The risk of ILD or pneumonia is of concern
.

Trastuzumab deruxtecan was superior to trastuzumab emtansine in reducing the risk of disease progression or death in patients with HER2-positive metastatic breast cancer who had progressed on trastuzumab plus paclitaxel, but interstitial lung disease after trastuzumab deruxtecan or pneumonia risk is of concern
.
Trastuzumab deruxtecan was superior to trastuzumab emtansine in reducing the risk of disease progression or death in patients with HER2-positive metastatic breast cancer who had progressed on trastuzumab plus paclitaxel, but interstitial lung disease after trastuzumab deruxtecan or pneumonia risk is of concern
.

Original source:
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Leave a comment here